Technology ID
TAB-3775

Transgenic Mice with Conditionally Activated Islet Beta Cell M3 Muscarinic Acetylcholine Receptor for Improving Glucose Tolerance in High-fat Diet Obese Insulin-resistant Mice

E-Numbers
E-454-2013-0
Lead Inventor
Wess, Jurgen (NIDDK)
Applications
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NIDDK
ICs
NIDDK
This technology includes transgenic mice in which designer rat M3 muscarinic receptor mutants were expressed only in islet 13-cells (directed by rat insulin promoter II), were unable to bind acetylcholine (the endogenous ligand) but could be selectively activated by an otherwise pharmacologically inert compound (clozapine-N-oxide (CNO)). The R-q receptor contained a Y148C point mutation, which enabled CNO to selectively activate G proteins of the Gq/11 family. The R-5 receptor contained an A238G mutation, which enabled CNO to selectively activate G proteins of the G5 family.
Commercial Applications
CNO-treatment that selectively activated 13-cell Gq111 increased first and second phase insulin release, greatly improved glucose tolerance in high-fat diet obese insulin-resistant mice, and increased 13-cell mass.

Competitive Advantages
Novel mouse model.
Licensing Contact:
Shastri, Mythreyi
shastrim@mail.nih.gov